Fate Therapeutics
FATE
$5.06
Share price
-4.08%
Change (1 day)
-23.29%
Change (1 year)
Categories
EPS for Fate Therapeutics (FATE)
EPS in 2023 (TTM): -$2.17
According to Fate Therapeutics 's latest financial reports the company's current EPS (TTM) is -$2.17. In 2022 the company made an earnings per share (EPS) of -$2.91 a decrease over its 2021 EPS that were of -$2.23.
EPS history for Fate Therapeutics from 2013 to 2023
Annual EPS
| Year | EPS | Change |
|---|---|---|
| 2023 (TTM) | -$2.17 | -25.43% |
| 2022 | -$2.91 | 30.49% |
| 2021 | -$2.23 | 7.21% |
| 2020 | -$2.08 | 45.45% |
| 2019 | -$1.43 | 19.17% |
| 2018 | -$1.20 | 17.65% |
| 2017 | -$1.02 | -3.77% |
| 2016 | -$1.06 | -12.4% |
| 2015 | -$1.21 | -3.97% |
| 2014 | -$1.26 | -2.09% |
| 2013 | -$1.29 |
EPS for similar companies or competitors
| Company | EPS | EPS differencediff. | Country |
|---|---|---|---|
 Becton Dickinson BDX | $5.55 | -355.76% | 🇺🇸 USA |
 Sarepta Therapeutics
SRPT | -$7.83 | 260.83% | 🇺🇸 USA |
 PTC Therapeutics
PTCT | -$8.65 | 298.62% | 🇺🇸 USA |
 Neurocrine Biosciences
NBIX | $1.96 | -190.32% | 🇺🇸 USA |
 Avidity Biosciences RNA | -$3.10 | 42.86% | 🇺🇸 USA |